SCHEMBL13616030

SCHEMBL13616030

Brc1ccc2c3ccc(Br)cc3c3c4cc(Br)ccc4c4ccc(Br)cc4c3c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2 P10415 1/20 0.45
CYP2A6 P11509 2/20 0.41
JAK2 O60674 3/20 0.39
CHEK1 O14757 3/20 0.39
METAP2 P50579 1/20 0.39
AURKA O14965 1/20 0.39
DAPK3 O43293 1/20 0.39
PRKD3 O94806 1/20 0.39
MAP4K4 O95819 1/20 0.39
PAK4 O96013 1/20 0.39
ABL1 P00519 1/20 0.39
NTRK1 P04629 1/20 0.39
CSF1R P07333 1/20 0.39
RET P07949 1/20 0.39
MET P08581 1/20 0.39
PDGFRB P09619 1/20 0.39
PIM1 P11309 1/20 0.39
FGFR1 P11362 1/20 0.39
PDGFRA P16234 1/20 0.39
PRKACA P17612 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13616027 0.89 BCL2 (0.44) BCL2CYP2A6JAK2CHEK1METAP2
SCHEMBL13616029 0.89 BCL2 (0.44) BCL2CYP2A6JAK2CHEK1METAP2
SCHEMBL13616023 0.89 BCL2 (0.44) BCL2CYP2A6JAK2CHEK1METAP2
SCHEMBL19396968 0.89 BCL2 (0.44) BCL2CYP2A6JAK2CHEK1METAP2
SCHEMBL13616024 0.89 BCL2 (0.44) BCL2CYP2A6JAK2CHEK1METAP2
SCHEMBL31049230 0.88 BCL2 (0.50) BCL2CYP2A6JAK2CHEK1METAP2
SCHEMBL19396754 0.87 MEN1 (0.46) BCL2CYP2A6CHEK1PRKD3MAP4K4
SCHEMBL16158369 0.87 CYP2A6 (0.47) BCL2CYP2A6JAK2CHEK1METAP2
SCHEMBL21176157 0.84 MEN1 (0.47) BCL2CYP2A6PRKD3MAP4K4CSF1R
SCHEMBL12589215 0.80 MEN1 (0.41) BCL2CYP2A6JAK2CHEK1METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090273278-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-11-05 US disclosed
US-20090273278-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090273278-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same OCIAD1, OCIAD2, ORMDL3 BCL2 2348/4885CYP2A6 1132/4885JAK2 4018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.